

Articles + Publications | March 16, 2023

Cash Is King in Biotech M&A, but Will Clinical Data Be a Saving Grace?

WRITTEN BY

Christopher S. Miller

Troutman Pepper attorney Christopher Miller recently authored *Reuters Legal News* article “[Cash Is King in Biotech M&A, but Will Clinical Data Be a Saving Grace?](#)” where he discusses strategic considerations for biotech companies entering into M&A transactions based on recent market trends.

RELATED INDUSTRIES + PRACTICES

- [Health Care + Life Sciences](#)
- [Life Sciences Transactions](#)